Jun 26, 2023 7:00am EDT Tonix Pharmaceuticals Enters into Agreement to Acquire Two FDA-Approved, Marketed Migraine Products from Upsher-Smith Laboratories, LLC
Jun 15, 2023 7:00am EDT Tonix Pharmaceuticals Announces Publication of Results from Phase 3 RELIEF Trial of TNX-102 SL for the Management of Fibromyalgia
Jun 7, 2023 7:00am EDT Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (anti-CD40L mAb) for the Prevention of Rejection in Kidney and Heart Allograft Transplantation in Animal Models at the 2023 American Transplant Congress
Jun 5, 2023 7:00am EDT Tonix Pharmaceuticals Announces Presentation of Data Supporting Development of Racemic and Single (S)-Isomer Tianeptine, Plastogen Anti-Depressants, at the American Society of Clinical Psychopharmacology Meeting
May 31, 2023 7:00am EDT Tonix Pharmaceuticals Announces Presentations Involving TNX-1500 (anti-CD40L mAb) at the 2023 American Transplant Congress
May 30, 2023 7:00am EDT Tonix Pharmaceuticals Announces Presentation at the 2023 BIO International Convention
May 25, 2023 4:05pm EDT Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
May 25, 2023 7:00am EDT Tonix Pharmaceuticals Announces Poster Presentation at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
May 23, 2023 7:00am EDT Tonix Pharmaceuticals Announces the Isolation and Characterization of the (S)-Isomer of Tianeptine, TNX-4300 (Estianeptine), Now Under Development for Psychiatric and Neurodegenerative Diseases
